Literature DB >> 26820628

Genetic and clinical data reinforce the role of GAS6 and TAM receptors in liver fibrosis.

Montserrat Marí1, Anna Tutusaus2, Pablo García de Frutos2, Albert Morales2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 26820628     DOI： 10.1016/j.jhep.2015.11.042

Source DB:  PubMed          Journal:  J Hepatol        ISSN： 0168-8278            Impact factor:   25.083


× No keyword cloud information.
  6 in total

1.  Bone morphogenetic protein-9/activin-like kinase 1 axis a new target for hepatic regeneration and fibrosis treatment in liver injury.

Authors:  Montserrat Marí; Albert Morales
Journal:  Hepatobiliary Surg Nutr       Date:  2017-12       Impact factor: 7.293

2.  Targeting of TAM Receptors Ameliorates Fibrotic Mechanisms in Idiopathic Pulmonary Fibrosis.

Authors:  Milena S Espindola; David M Habiel; Rohan Narayanan; Isabelle Jones; Ana L Coelho; Lynne A Murray; Dianhua Jiang; Paul W Noble; Cory M Hogaboam
Journal:  Am J Respir Crit Care Med       Date:  2018-06-01       Impact factor: 21.405

3.  Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span.

Authors:  Alexander V Misharin; Luisa Morales-Nebreda; Paul A Reyfman; Carla M Cuda; James M Walter; Alexandra C McQuattie-Pimentel; Ching-I Chen; Kishore R Anekalla; Nikita Joshi; Kinola J N Williams; Hiam Abdala-Valencia; Tyrone J Yacoub; Monica Chi; Stephen Chiu; Francisco J Gonzalez-Gonzalez; Khalilah Gates; Anna P Lam; Trevor T Nicholson; Philip J Homan; Saul Soberanes; Salina Dominguez; Vince K Morgan; Rana Saber; Alexander Shaffer; Monique Hinchcliff; Stacy A Marshall; Ankit Bharat; Sergejs Berdnikovs; Sangeeta M Bhorade; Elizabeth T Bartom; Richard I Morimoto; William E Balch; Jacob I Sznajder; Navdeep S Chandel; Gökhan M Mutlu; Manu Jain; Cara J Gottardi; Benjamin D Singer; Karen M Ridge; Neda Bagheri; Ali Shilatifard; G R Scott Budinger; Harris Perlman
Journal:  J Exp Med       Date:  2017-07-10       Impact factor: 14.307

4.  Liver X Receptor Inverse Agonist SR9243 Suppresses Nonalcoholic Steatohepatitis Intrahepatic Inflammation and Fibrosis.

Authors:  Peng Huang; Benson Kaluba; Xiao-Lin Jiang; Shi Chang; Xiao-Feng Tang; Lin-Feng Mao; Zhi-Peng Zhang; Fei-Zhou Huang
Journal:  Biomed Res Int       Date:  2018-02-18       Impact factor: 3.411

5.  A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target.

Authors:  Anna Tutusaus; Estefanía de Gregorio; Blanca Cucarull; Helena Cristóbal; Cristina Aresté; Isabel Graupera; Mar Coll; Anna Colell; Gro Gausdal; James B Lorens; Pablo García de Frutos; Albert Morales; Montserrat Marí
Journal:  Cell Mol Gastroenterol Hepatol       Date:  2019-11-02

Review 6.  Gas6/TAM Signaling Components as Novel Biomarkers of Liver Fibrosis.

Authors:  Carlo Smirne; Cristina Rigamonti; Carla De Benedittis; Pier Paolo Sainaghi; Mattia Bellan; Michela Emma Burlone; Luigi Mario Castello; Gian Carlo Avanzi
Journal:  Dis Markers       Date:  2019-09-08       Impact factor: 3.434
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.